为了摆脱国内市场过度依赖进口原研药的尴尬局面，近年来，政府从财政到政策大力支持推动药物研发，药品研发逐渐火热。仿制药实用、周期短，但全新的一类新药研制才是我国医药的核心竞争力，作为化学合成物，1.1 类新药可以说是中国药企走向国际舞台的必备王牌。

2013年中国战略性新兴产业总体呈现良好发展态势，保持了相对较快的产业增速。展望2014年，全球经济将延续缓慢复苏的步伐，而中国转经济、调结构也进入攻坚期和深水区，战略性新兴产业有望迎来快速发展的最佳契机，成为引领经济增长的重要引擎。

6月，随着市场需求的好转，医药行业产销规模有所扩大。其中，中成药产量环比增长18.12%，化学原料药产量环比增长5.98%，中西药品类零售总额环比增长7.0%。在药品价格调控的引导下，医药制造业工业品出厂价格指数逐步趋稳，6月为100.72点，比上月微降0.01点。下半年，随着各省药品招标进程逐步加快，下游需求将回暖，再加上行业政策逐渐明朗，企业将逐渐走出新版GMP认证带来的负面影响，预计医药行业发展速度将有所上升。

论文以生物技术药物产业为研究对象，分析总结了生物技术药物的特性、现阶段主要上市产品、研究重点领域和发展前景。论文还研究了我国生物技术药物产业的现状，并借鉴国外经验，提出了发展我国生物技术药物产业的对策建议。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

A platform technology to prepare enzyme sensitive nanomedicine (ESNM), which integrates the imaging and treatment capability, has been developed to report and cure diseases. ESNM is prepared with multiple layers of polyelectrolytes, sequentially assembled on an inert gold nanoparticle, using alternating charged polymers. Potentially the release kinetics could be controlled by varying polyelectrolytes with different properties, such as length, ionic strength and bond stability. Upon incubation with cells, the assembled ESNMs are taken up efficiently. The tight packing and layered assembly of the quenched polyelectrolytes slow subsequent intracellular degradation, and then result in a prolonged intracellular fluorescence signal and therapeutic effect for up to 3 weeks with no noticeable toxicity.

Nanomedicine is a relatively new field of science and technology. By interacting with biomolecules, therefore at nanoscale, nanotechnology opens up a vast field of research and application. Current and potential applications of nanotechnology in medicine range from research involving diagnostic devices, drug delivery vehicles to enhanced gene therapy and tissue engineering procedures. Its advantage over conventional medicine lies on its size. Operating at nanoscale allows to exploit physical properties different from those observed at microscale such as the volume/surface ratio. This allows drugs of nanosize be used in lower concentration and has an earlier onset of therapeutic action. It also provides materials for controlled drug delivery by directing carriers to a specific location. Inorganic nanomedicine is likely to remain one of the most prolific fields of nanomedicine, which refers to the use of inorganic or hybrid (inorganic-inorganic or inorganic-organic) nanomaterials (ESfMs) and nanoparticles (INPs) to achieve innovative medical advances for body parts implantation, drug and gene discovery and delivery, discovery of biomarkers, and molecular diagnostics. Among the most promising INMs being developed are metal, silica, dendrimers, organic-inorganic hybrids, ceramics (e.g. ZrO_2, TiO_2, Al_2O_3, etc.) and bioinorganic hybrids. Metal NP contrast agents enhance magnetic resonance imaging and ultrasound results in biomedical applications of in vivo imaging. Hollow and porous INMs have been exploited for drug and gene delivery, diagnostic imaging, and photothermal therapy. Biomolecular inorganic nanohybrids and nanostructured biomaterials have been exploited for targeted imaging and therapy, drug and gene delivery, and regenerative medicine. Potential uses for fluorescent quantum dots (QDs) include cell labeling, biosensing, in vivo imaging, bimodal magnetic-luminescent imaging, and diagnostics. Biocompatible QD conjugates have been used successfully for sentinel lymph node mapping, tumor targeting, tumor angiogenesis imaging, and metastasis cell tracking. This article outlines present developments and future prospects for the use of Ti-based NPs and NMs in experimental in vivo and in vitro studies and in engineering nanodevices and biosensors for clinical and investigative use in diagnosis and therapy in diverse fields of medical sciences, such as oncology, infection control, orthopedics, dentistry, dermatology, genetics, cardiology, ophthalmology, etc. Toxicological considerations of these INPs and INMs are also discussed.

本刊以七大战略性新兴产业——节能环保、新一代信息技术、生物、高端装备制造、新能源、新材料、新能源汽车为研究重点，关注国家高层和各部委的动态，剖析国家和地方的新兴产业政策。本刊设有政策导读、领导讲话、七大战略性新兴产业本周国内外行业动态和重点企业新闻、投资专题四大板块，能够实时监测新兴产业和重点企业动态，把握新兴产业发展方向，研究发展重点，寻求发展机遇。

本刊以七大战略性新兴产业——节能环保、新一代信息技术、生物、高端装备制造、新能源、新材料、新能源汽车为研究重点，关注国家高层和各部委的动态，剖析国家和地方的新兴产业政策。本刊设有政策导读、领导讲话、七大战略性新兴产业本周国内外行业动态和重点企业新闻、投资专题四大板块，能够实时监测新兴产业和重点企业动态，把握新兴产业发展方向，研究发展重点，寻求发展机遇。

本刊以七大战略性新兴产业——节能环保、新一代信息技术、生物、高端装备制造、新能源、新材料、新能源汽车为研究重点，关注国家高层和各部委的动态，剖析国家和地方的新兴产业政策。本刊设有政策导读、领导讲话、七大战略性新兴产业本周国内外行业动态和重点企业新闻、投资专题四大板块，能够实时监测新兴产业和重点企业动态，把握新兴产业发展方向，研究发展重点，寻求发展机遇。